![Defining New Reference Intervals for Serum Free Light Chains in Individuals with Reduced Kidney Function: Results of the Population- Based on iStopMM Study Defining New Reference Intervals for Serum Free Light Chains in Individuals with Reduced Kidney Function: Results of the Population- Based on iStopMM Study](https://imf-d8-prod.s3.us-west-1.wasabisys.com/2021-12/Long-iStopMM-Results.jpg)
Defining New Reference Intervals for Serum Free Light Chains in Individuals with Reduced Kidney Function: Results of the Population- Based on iStopMM Study
Comparison of Dako's and Beckman Coulter's anti-Kappa and Lambda light chains antibodies with protocols including 1, 2 or 3
![Phenotyping Polyclonal Kappa and Lambda Light Chain Molecular Mass Distributions in Patient Serum Using Mass Spectrometry | Journal of Proteome Research Phenotyping Polyclonal Kappa and Lambda Light Chain Molecular Mass Distributions in Patient Serum Using Mass Spectrometry | Journal of Proteome Research](https://pubs.acs.org/cms/10.1021/pr5005967/asset/images/medium/pr-2014-005967_0009.gif)
Phenotyping Polyclonal Kappa and Lambda Light Chain Molecular Mass Distributions in Patient Serum Using Mass Spectrometry | Journal of Proteome Research
![Table 2 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar Table 2 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1444d9fcd1aa06934208ca29e69340f3ca084cbe/3-Table2-1.png)
Table 2 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar
![Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study | Blood Cancer Journal Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study | Blood Cancer Journal](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41408-022-00732-3/MediaObjects/41408_2022_732_Fig1_HTML.png)
Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study | Blood Cancer Journal
![Measuring Serum Free Light Chains (FLC) Improves Diagnosis and Prognosis for Patients with Monclonal Gammopathies - Warde Medical Laboratory Measuring Serum Free Light Chains (FLC) Improves Diagnosis and Prognosis for Patients with Monclonal Gammopathies - Warde Medical Laboratory](https://wardelab.com/wp-content/uploads/2020/06/18_2_4.jpg)
Measuring Serum Free Light Chains (FLC) Improves Diagnosis and Prognosis for Patients with Monclonal Gammopathies - Warde Medical Laboratory
Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma | Haematologica
Comparison of Dako's and Beckman Coulter's anti-Kappa and Lambda light chains antibodies with protocols including 1, 2 or 3
![JCM | Free Full-Text | The Role of Light Kappa and Lambda Chains in Heart Function Assessment in Patients with AL Amyloidosis JCM | Free Full-Text | The Role of Light Kappa and Lambda Chains in Heart Function Assessment in Patients with AL Amyloidosis](https://www.mdpi.com/jcm/jcm-10-01274/article_deploy/html/images/jcm-10-01274-g001.png)